| Description | The antibody CV05-163 is a human mAb specific for SARS-CoV-2 Spike S1 protein. It has no somatic mutations, and binds to SARS-CoV-2 RBD with a KD of 0.2 nM as an IgG and 45.3 nM as a Fab. The antibody also exhibited high neutralization potency with an IC50 of 16.3 ng/ml against authentic SARS-CoV-2. It also extensively interacts with RBD-E484 via H-bonds (VH W50 and VH N58) and a salt bridge (VL R91) that explains why the binding and neutralization by the antibody were diminished by the E484K mutant. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | Receptor-binding domain (RBD) |
| Affinity | The antibody CV05-163 binds RBD with a KD of 0.2 nM as an IgG and 45.3 nM as a Fab. |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA, Neut |
| Application Notes | The antibody CV05-163 also exhibited high neutralization potency with an IC50 of 16.3 ng/ml against authentic SARS-CoV-2. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Western Blot Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
